Overview
Thyrotropin-releasing hormone (TRH), pharmaceutically named protirelin, is the hypothalamic tripeptide pyroGlu-His-Pro-NH2 that stimulates the anterior pituitary to release thyroid-stimulating hormone and prolactin. It is an endogenous human hormone, not a designer research peptide.
Both terminal modifications matter chemically. The N-terminal pyroglutamate is cyclised and the C-terminus is amidated; together these block the exopeptidases that would otherwise rapidly degrade a free tripeptide, and both are required for receptor activity.
Historically, protirelin was used as a diagnostic agent: administering it and measuring the TSH response probed pituitary function and helped distinguish causes of thyroid dysfunction. That role has largely been superseded by sensitive TSH immunoassays, which answer most of the same questions from a single blood draw. A search of the openFDA drug label database in this session returned no current label for protirelin, consistent with it no longer being actively marketed in the US.
TRH receptors are also present in the central nervous system beyond the pituitary, which is the basis for interest in its neurological and cognitive effects. That interest is long-standing but has not produced an approved neurological or nootropic indication — and any compound that acutely stimulates TSH and prolactin release has endocrine consequences that make casual use inadvisable.
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- Well-established endocrine pharmacology in humans from its use as a diagnostic agent: administration reliably stimulates TSH and prolactin release.
- AnimalRodent and other animal models
- Extensive endocrine and neuroscience literature on TRH physiology.
- In vitroCell and tissue studies
- TRH receptor binding and signalling are well characterised.
Key studies & findings
1 study- 1
A query of the openFDA drug label database returned no current label for protirelin, indicating it is not actively marketed in the US, in contrast to triptorelin and menotropins which returned active labels.
Benefits & effects
2 documentedReliable stimulation of pituitary TSH release for diagnostic testing
Stimulation of prolactin release
Side effects & safety
3 reportedSafety noteResearch compound for laboratory use only. Not approved for human use; no established human safety database outside the trials cited here.
Acute TSH and prolactin elevation
Transient effects reported with intravenous administration including urge to urinate and flushing
Sustained prolactin elevation is not benign
Limitations & open questions
TRH's diagnostic role has largely been displaced by sensitive TSH immunoassays, and no current US label was located. Cognitive and neurological interest in TRH is long-standing but has not yielded an approved indication. Because the compound acutely raises TSH and prolactin, use outside a controlled diagnostic setting carries endocrine consequences — sustained prolactin elevation in particular is not benign.
Pharmacology
Protirelin is the tripeptide pyroGlu-His-Pro-NH2 (C16H22N6O4, MW 362.38, CAS 24305-27-9, PubChem CID 638678). The cyclised N-terminal pyroglutamate and C-terminal amide both block exopeptidase degradation and are required for receptor activity. It was administered intravenously in its diagnostic use, where the TSH response is measured over the following minutes.
Frequently asked questions
Is TRH a research peptide or a hormone?
It is an endogenous human hormone — the hypothalamic tripeptide that tells the pituitary to release TSH and prolactin. Its pharmaceutical name is protirelin.
Is protirelin still available as a drug?
No current FDA label was found in the openFDA database in this session, consistent with it no longer being actively marketed in the US. Its diagnostic role was largely replaced by sensitive TSH immunoassays.
Why do the pyroglutamate and amide groups matter?
They block the exopeptidases that would otherwise degrade a free tripeptide almost immediately, and both are required for activity at the TRH receptor. A plain Glu-His-Pro tripeptide would not work.
Does TRH have cognitive effects?
TRH receptors exist in the CNS beyond the pituitary and there is a long research interest in neurological effects, but this has not produced an approved neurological or cognitive indication. Meanwhile the compound reliably raises TSH and prolactin, which is not a trivial endocrine action.